A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil
Early Gastric Cancer Patients Who Were Scheduled for Endoscopic Submucosal Dissection
About this trial
This is an interventional treatment trial for Early Gastric Cancer Patients Who Were Scheduled for Endoscopic Submucosal Dissection focused on measuring Endoscopic submucosal dissection, propofol, remifentanil, dexmedetomidine, efficacy, safeness
Eligibility Criteria
Inclusion Criteria:
- Age ≥20
- American Society of Anaesthesiologists(ASA) physical status classification I~III
- Early gastric cancer patients who were scheduled for Endoscopic submucosal dissection
Exclusion Criteria:
- Age < 20
- American Society of Anaesthesiologists(ASA) physical status classification IV
- those with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure)
- known drug allergies or history of drug abuse
- psychological disease
Sites / Locations
- Anesthesiology & Pain Medicine, Yonsei university college of medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
DR group
PR group
In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).